Primary Malignant Lymphoma of the Oral Cavity and Paranasal Sinuses

Wang, C. C.

doi:10.1148/100.1.151

Cited by 52 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this update of the authors' experience with sinonasal lymphomas, the clinical presentation was similar to that previously reported from MDACC as well as others in Western countries 2, 22, 30‐40. Patients tend to be elderly males with locally advanced tumors.…”

Section: Discussionsupporting

confidence: 82%

“…Reported 5‐year survival rates for sinonasal lymphomas have ranged from 12‐86% 1, 2, 20, 22, 30‐40, 58‐60. The combination of a broad distribution of survival rates and variable patterns of recurrence has resulted in diverse therapy recommendations.…”

Section: Discussionmentioning

confidence: 99%

“…The majority of the lesions were locally advanced (Table 1) and involved multiple anatomic structures, making the assignment of primary site to the nasal cavity or maxillary sinus somewhat arbitrary in very large tumors 22. However, a primary site was assigned to each case according to the location of the greatest bulk of disease and the apparent center of the tumor.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Lymphoma of the nasal cavity and paranasal sinuses

Logsdon

Kavadi

et al. 1997

Cancer

116

View full text Add to dashboard Cite

BACKGROUND Lymphoma of the nasal cavity and paranasal sinuses is a rare presentation of extranodal lymphoma with a natural history that is not well characterized in this era of combination chemotherapy. The goals of this retrospective study were 1) to define the natural history of sinonasal lymphomas; 2) to compare the results of radiation therapy (XRT) alone with those of combined modality therapy (CMT) in the treatment of patients with lymphoma of the nasal cavity and paranasal sinuses; and 3) to define prognostic factors for each treatment. METHODS Between 1947 and 1993, 70 patients with newly diagnosed lymphoma of the nasal cavity and paranasal sinuses were treated. The Ann Arbor stages were: Stage IE: 42 patients; Stage IIE: 14 patients; Stage IIIE: 2 patients; and Stage IV: 12 patients. The distribution of T classifications of the primary tumors was as follows: T1: 2 patients; T2: 16; T3: 18; and T4: 34. Greater than 90% of the patients had intermediate grade lymphoma (Working Formulation), and none had follicular lymphoma. Twenty‐eight patients received XRT alone, and 42 received CMT. RESULTS The actuarial 5‐year freedom from progression (FFP) and overall survival (OS) rates for the entire group were 57% and 52%, respectively. For patients with localized disease (Stages IE and IIE) receiving CMT, the actuarial 5‐year FFP and OS were 83% and 67%, respectively. In multivariate analysis, treatment with CMT (P = 0.0005) and stage (IE vs. IIIE‐IV) (P = 0.0001) were associated with improved FFP. In the group of patients receiving XRT, extent of disease (Stage IE, T1‐3 vs. Stage IE, T4 vs. Stage IIE‐IV) (P = 0.0001) was the only clinical characteristic associated with improved FFP in multivariate analysis. For patients receiving CMT, International Index (0 vs. 1‐3 vs. 4, 5) (P = 0.0001) was the only significant factor predictive of improved FFP in multivariate analysis. One patient failed in the central nervous system (CNS) after initial therapy as a result of a radiation therapy marginal miss. CONCLUSIONS In a Western population, patients with localized lymphoma of the nasal cavity and paranasal sinuses have a favorable prognosis when treated with CMT. FFP is significantly improved by treatment with CMT. For patients treated with XRT, extent of disease is the strongest predictor of outcome. International Index is the most significant prognostic factor for patients receiving CMT. Failure in the CNS is rare after initial therapy and is associated with local failure. Cancer 1997; 80:477‐88. © 1997 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lymphoma of the nasal cavity and paranasal sinuses

Logsdon

Kavadi

et al. 1997

Cancer

116

View full text Add to dashboard Cite

show abstract

“…[15] There are several reports of malignant lymphoma of the head and neck region. [16–18] Till date only, four cases of NHL of accessory parotid gland have been reported in English literature. [235]…”

Section: Discussionmentioning

confidence: 99%

Accessory parotid gland tumors

Ramachar¹,

Huliyappa²

2012

Ann Maxillofac Surg

View full text Add to dashboard Cite

Tumors of accessory parotid gland are considered in the differential diagnosis of a mid cheek mass. Parotidectomy is the procedure of choice. All pathological types of parotid main gland tumors occur in the accessory parotid gland also. Presenting as a mid cheek or infrazygomatic mass, the tumors of this accessory parotid gland are notorious for recurrences, if adequate margins are not achieved. We describe two such cases of such a tumor. 40-year-old male with a slowly progressive mid cheek mass was operated by a mid cheek incision. Histopathology of the tumor was pleomorphic adenoma. Facial nerve paresis recovered complelety in 6 months. A 52-year-old female with progressive mid cheek mass who underwent parotidectomy and neck dissection by a modified Blair's incision was diagnosed with extranodal marginal zone lymphoma with focal transformation to a diffuse large B-cell lymphoma. Chemotherapy with CHOP regime was initiated. There was no recurrence at 6 months of follow-up. Lymphoma of accessory parotid gland is a very rare tumor. Standard parotidectomy incision is advocated to prevent damage to facial nerve branches.

show abstract

“…The most common error was to interpret lymphomas as anaplastic carcinoma. In another series, Wang 14 reported that the histologic diagnosis of lymphoma could not be made in 9 of 30 (24%) patients on the in- itial biopsy of those lesions presenting in the oral cavity and paranasal sinuses. He observed that the lesions occasionally had a gross appearance indistinguishable from ulcerative squamous cell carcinoma.…”

Section: • 14mentioning

confidence: 99%

Diagnosis of Malignant Lymphomas of the Nasal Cavity, Paranasal Sinuses and Nasopharynx

et al. 1983

View full text Add to dashboard Cite

The diagnosis of non-Hodgkin's malignant lymphoma of the nasal cavity, paranasal sinuses, and nasopharynx was made in 15 patients over a 7 year period (nasopharynx, 9; nasal cavity, 3; maxillary sinus, 2; frontal sinus, 1). A wide variety of head and neck symptoms, often characteristic of benign disease, was reported ranging from 2 weeks to 4 months prior to presentation. Of the 15 cases, the original diagnosis was inconclusive in 6; 4 of the 6 required rebiopsy, while the diagnosis in the other 2 was confirmed on further pathologic consultation. Tissue marker studies, which have recently become available, were performed in 7 cases and were crucial in the diagnosis of 2. B-cell lymphoma was diagnosed in the 7 patients who had tissue marker studies. Five patients had palpable cervical nodes, and none had distant adenopathy or masses. With further staging, 4 of the 15 patients were found to have disseminated disease. The paper emphasizes the need for early biopsy of suspicious lesions presenting in areas in which physical examination is limited. Recommendations are made for handling the biopsy specimen when malignant lymphoma is suspected, as well as for the evaluation of local and distant sites. The role of surgery is primarily diagnostic in patients with malignant lymphoma.

show abstract

Primary Malignant Lymphoma of the Oral Cavity and Paranasal Sinuses

Cited by 52 publications

References 1 publication

Lymphoma of the nasal cavity and paranasal sinuses

Lymphoma of the nasal cavity and paranasal sinuses

Accessory parotid gland tumors

Diagnosis of Malignant Lymphomas of the Nasal Cavity, Paranasal Sinuses and Nasopharynx

Contact Info

Product

Resources

About